Quick Answer
Co-Diagnostics, Inc. reported Research And Development Expense of $19.14 million for the year ending 2025.
- Co-Diagnostics, Inc. showed a decrease of -8.8% in Research And Development Expense from 2024 to 2025.
- This data is from Co-Diagnostics, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2016: $172.1 thousand | Q3 2016: $172.8 thousand | Q1 2017: $265.7 thousand | Q2 2017: $184.9 thousand | Q3 2017: $272.2 thousand | Q1 2018: $297.4 thousand | Q2 2018: $357.9 thousand | Q3 2018: $330.4 thousand | Q1 2019: $347.3 thousand | Q2 2019: $312.6 thousand | Q3 2019: $331.0 thousand | Q1 2020: $400.0 thousand | Q2 2020: $750.2 thousand | Q3 2020: $921.9 thousand | Q1 2021: $2.22 million | Q2 2021: $4.67 million | Q3 2021: $5.89 million | Q1 2022: $3.77 million | Q2 2022: $3.89 million | Q3 2022: $5.04 million | Q1 2023: $5.01 million | Q2 2023: $5.98 million | Q3 2023: $5.79 million | Q1 2024: $5.68 million | Q2 2024: $5.61 million | Q3 2024: $4.88 million | Q1 2025: $4.87 million | Q2 2025: $4.69 million | Q3 2025: $4.48 million.
- Over the full 10 years of available data (2016 to 2025), Co-Diagnostics, Inc.'s Research And Development Expense has grown by 2,516.3%.
- Historical annual values: Fiscal year 2025: $19.14 million | Fiscal year 2024: $20.98 million | Fiscal year 2023: $22.96 million | Fiscal year 2022: $17.44 million | Fiscal year 2021: $14.96 million | Fiscal year 2020: $3.19 million | Fiscal year 2019: $1.37 million | Fiscal year 2018: $1.36 million | Fiscal year 2017: $1.00 million | Fiscal year 2016: $731.5 thousand.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: